• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary.

作者信息

Huang Yuan Yu Michael, Hsu Sylvia

机构信息

Department of Dermatology, Baylor College of Medicine, Houston, Texas.

Department of Dermatology, Baylor College of Medicine, Houston, Texas.

出版信息

J Am Acad Dermatol. 2017 Jun;76(6):e221. doi: 10.1016/j.jaad.2017.02.016.

DOI:10.1016/j.jaad.2017.02.016
PMID:28522069
Abstract
摘要

相似文献

1
Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary.司库奇尤单抗治疗银屑病在24至32周时疗效丧失：最新情况及评论
J Am Acad Dermatol. 2017 Jun;76(6):e221. doi: 10.1016/j.jaad.2017.02.016.
2
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.司库奇尤单抗，一种全人源抗白细胞介素-17A 单克隆抗体，在中重度斑块型银屑病患者中显示出最小的免疫原性。
Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.
3
Secukinumab in the treatment of psoriasis: an update.司库奇尤单抗治疗银屑病：最新进展
Immunotherapy. 2017 Mar;9(3):229-238. doi: 10.2217/imt-2016-0128. Epub 2017 Feb 6.
4
Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.使用自动注射器给药司库奇尤单抗在52周内持续减轻斑块状银屑病的严重程度：随机对照JUNCTURE试验的结果
J Eur Acad Dermatol Venereol. 2017 May;31(5):847-856. doi: 10.1111/jdv.14073. Epub 2017 Jan 23.
5
Secukinumab in plaque psoriasis--results of two phase 3 trials.司库奇尤单抗治疗斑块状银屑病的两项 3 期临床试验结果。
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
6
Secukinumab (AIN457) for the treatment of psoriasis.司库奇尤单抗（AIN457）用于治疗银屑病。
Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1.
7
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.司库奇尤单抗治疗中重度银屑病长达 3 年，疗效持续良好且安全性良好：一项双盲扩展研究的结果。
Br J Dermatol. 2017 Oct;177(4):1033-1042. doi: 10.1111/bjd.15706. Epub 2017 Sep 4.
8
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).司库奇尤单抗治疗银屑病：评估部分应答者改善治疗应答潜力的随机、对照 3 期临床试验结果（STATURE）。
Br J Dermatol. 2015 Sep;173(3):777-87. doi: 10.1111/bjd.13814. Epub 2015 May 16.
9
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.司库奇尤单抗在日本中重度斑块状银屑病患者中的疗效和安全性：来自ERASURE（一项随机、安慰剂对照的3期研究）的亚组分析
J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30.
10
Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks.司库奇尤单抗在24至32周时对银屑病的疗效丧失。
J Am Acad Dermatol. 2016 Oct;75(4):e169. doi: 10.1016/j.jaad.2016.05.049.

引用本文的文献

1
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.替拉珠单抗用于斑块状银屑病连续给药、治疗中断、剂量调整及从依那西普转换治疗的疗效和安全性：III期研究结果
Br J Dermatol. 2020 Jun;182(6):1359-1368. doi: 10.1111/bjd.18484. Epub 2019 Nov 19.